XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Ordinary shares
Preferred shares
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive (loss) income
Treasury shares
Beginning balance (in shares) at Dec. 31, 2019     42,927 0           5,407
Beginning balance at Dec. 31, 2019 $ (29,199)   $ 429 $ 0 $ 434,391   $ (391,215)   $ (22,806) $ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income (865)           (865)      
Other comprehensive income (loss) (821)               (821)  
Exercise of stock options (in shares)     146              
Exercise of stock options 1,389   $ 2   1,387          
Vesting of restricted shares (in shares)     19              
Vesting of restricted shares 0                  
Employee share purchase plan share issuance (in shares)     40              
Employee share purchase plan share issuance 88       88          
Stock-based compensation expense 742       742          
February 2020 private placement (in shares)     8,680 488            
February 2020 private placement 60,733   $ 87 $ 5 60,641          
Ending balance (in shares) at Mar. 31, 2020     51,812 488           5,407
Ending balance at Mar. 31, 2020 32,067   $ 518 $ 5 497,249   (392,080)   (23,627) $ (49,998)
Beginning balance (in shares) at Dec. 31, 2019     42,927 0           5,407
Beginning balance at Dec. 31, 2019 (29,199)   $ 429 $ 0 434,391   (391,215)   (22,806) $ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income 30,009                  
Ending balance (in shares) at Jun. 30, 2020     63,537 488           5,407
Ending balance at Jun. 30, 2020 182,125   $ 635 $ 5 615,207   (361,206)   (22,518) $ (49,998)
Beginning balance (in shares) at Dec. 31, 2019     42,927 0           5,407
Beginning balance at Dec. 31, 2019 $ (29,199)   $ 429 $ 0 434,391   (391,215)   (22,806) $ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Accounting Standards Update [Extensible Enumeration] us-gaap:AccountingStandardsUpdate202006Member                  
Ending balance (in shares) at Dec. 31, 2020     58,396 488            
Ending balance at Dec. 31, 2020 $ 162,266 $ (12,939) $ 583 $ 5 566,916 $ (26,699) (384,187) $ 13,760 (21,051)  
Beginning balance (in shares) at Mar. 31, 2020     51,812 488           5,407
Beginning balance at Mar. 31, 2020 32,067   $ 518 $ 5 497,249   (392,080)   (23,627) $ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income 30,874           30,874      
Other comprehensive income (loss) 1,109               1,109  
Exercise of stock options (in shares)     95              
Exercise of stock options 393   $ 1   392          
Employee share purchase plan share issuance 33       33          
Stock-based compensation expense 769       769          
February 2020 private placement (94)       (94)          
May 2020 public offering (in shares)     11,630              
May 2020 public offering 116,974   $ 116   116,858          
Ending balance (in shares) at Jun. 30, 2020     63,537 488           5,407
Ending balance at Jun. 30, 2020 182,125   $ 635 $ 5 615,207   (361,206)   (22,518) $ (49,998)
Beginning balance (in shares) at Dec. 31, 2020     58,396 488            
Beginning balance at Dec. 31, 2020 162,266 (12,939) $ 583 $ 5 566,916 (26,699) (384,187) 13,760 (21,051)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income (13,445)           (13,445)      
Other comprehensive income (loss) (1,255)               (1,255)  
Exercise of stock options (in shares)     23              
Exercise of stock options 106       106          
Vesting of restricted shares (in shares)     61              
Vesting of restricted shares 0   $ 1   (1)          
Employee share purchase plan share issuance (in shares)     8              
Employee share purchase plan share issuance 43       43          
Stock-based compensation expense 1,728       1,728          
Ending balance (in shares) at Mar. 31, 2021     58,488 488            
Ending balance at Mar. 31, 2021 136,504   $ 584 $ 5 542,093   (383,872)   (22,306)  
Beginning balance (in shares) at Dec. 31, 2020     58,396 488            
Beginning balance at Dec. 31, 2020 162,266 $ (12,939) $ 583 $ 5 566,916 $ (26,699) (384,187) $ 13,760 (21,051)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income (33,026)                  
Ending balance (in shares) at Jun. 30, 2021     58,488 488            
Ending balance at Jun. 30, 2021 118,880   $ 584 $ 5 544,094   (403,453)   (22,350)  
Beginning balance (in shares) at Mar. 31, 2021     58,488 488            
Beginning balance at Mar. 31, 2021 136,504   $ 584 $ 5 542,093   (383,872)   (22,306)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net (loss) income (19,581)           (19,581)      
Other comprehensive income (loss) (44)               (44)  
Stock-based compensation expense 2,001       2,001          
Ending balance (in shares) at Jun. 30, 2021     58,488 488            
Ending balance at Jun. 30, 2021 $ 118,880   $ 584 $ 5 $ 544,094   $ (403,453)   $ (22,350)